$1.62
+0.11 (+7.28%)
Open$1.52
Previous Close$1.51
Day High$1.66
Day Low$1.51
52W High$3.10
52W Low$1.07
Volume—
Avg Volume275.1K
Market Cap154.82M
P/E Ratio—
EPS$-0.40
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+467.9% upside
Current
$1.62
$1.62
Target
$9.20
$9.20
$6.27
$9.20 avg
$10.38
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 17.54M | 11.66M | 53.79M |
| Net Income | -45,258,707 | -27,074,002 | 2.31M |
| Profit Margin | -258.1% | -245.2% | 4.3% |
| EBITDA | -44,094,750 | -27,843,145 | 4.13M |
| Free Cash Flow | — | — | 1.88M |
| Rev Growth | +50.5% | +50.5% | +4.8% |
| Debt/Equity | 0.32 | 0.32 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |